CN102209728A - 急性淋巴细胞白血病的治疗方法 - Google Patents

急性淋巴细胞白血病的治疗方法 Download PDF

Info

Publication number
CN102209728A
CN102209728A CN2009801443998A CN200980144399A CN102209728A CN 102209728 A CN102209728 A CN 102209728A CN 2009801443998 A CN2009801443998 A CN 2009801443998A CN 200980144399 A CN200980144399 A CN 200980144399A CN 102209728 A CN102209728 A CN 102209728A
Authority
CN
China
Prior art keywords
mrd
patients
single chain
chain antibody
bispecific single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801443998A
Other languages
English (en)
Chinese (zh)
Inventor
格哈德·祖格迈尔
伊夫林·德根哈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41692882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102209728(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micromet GmbH filed Critical Micromet GmbH
Priority to CN201710366308.1A priority Critical patent/CN107184977A/zh
Publication of CN102209728A publication Critical patent/CN102209728A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801443998A 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法 Pending CN102209728A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710366308.1A CN107184977A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US61/112,323 2008-11-07
US18329109P 2009-06-02 2009-06-02
US61/183,291 2009-06-02
PCT/EP2009/007970 WO2010052014A1 (en) 2008-11-07 2009-11-06 Treatment of acute lymphoblastic leukemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710366308.1A Division CN107184977A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Publications (1)

Publication Number Publication Date
CN102209728A true CN102209728A (zh) 2011-10-05

Family

ID=41692882

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801443998A Pending CN102209728A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法
CN201710366308.1A Pending CN107184977A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710366308.1A Pending CN107184977A (zh) 2008-11-07 2009-11-06 急性淋巴细胞白血病的治疗方法

Country Status (26)

Country Link
US (3) US20130323247A1 (https=)
EP (2) EP2982696B1 (https=)
JP (2) JP5647132B2 (https=)
KR (1) KR101695327B1 (https=)
CN (2) CN102209728A (https=)
AU (4) AU2009313040B2 (https=)
BR (1) BRPI0921482B1 (https=)
CA (1) CA2742249C (https=)
CY (2) CY1117033T1 (https=)
DK (2) DK2342227T3 (https=)
ES (2) ES2558434T3 (https=)
HR (2) HRP20151168T1 (https=)
HU (2) HUE043326T2 (https=)
IL (1) IL212652A (https=)
LT (1) LT2982696T (https=)
ME (2) ME02363B (https=)
MX (1) MX2011002927A (https=)
NZ (1) NZ591311A (https=)
PL (2) PL2342227T3 (https=)
PT (2) PT2982696T (https=)
RS (2) RS58827B1 (https=)
RU (1) RU2536940C2 (https=)
SI (2) SI2342227T1 (https=)
SM (2) SMT201900278T1 (https=)
WO (1) WO2010052014A1 (https=)
ZA (1) ZA201103255B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105154440A (zh) * 2015-08-14 2015-12-16 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
CN106456731A (zh) * 2014-02-28 2017-02-22 詹森生物科技公司 用于治疗急性成淋巴细胞性白血病的抗cd38抗体
CN107995913A (zh) * 2015-05-18 2018-05-04 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN108884166A (zh) * 2016-02-19 2018-11-23 诺瓦斯科普知识产权有限公司 工程改造的细胞和方法
CN111315780A (zh) * 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150175T1 (en) * 2005-12-16 2015-03-27 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
KR101695327B1 (ko) * 2008-11-07 2017-01-11 암젠 리서치 (뮌헨) 게엠베하 급성 림프구성 백혈병의 치료방법
RS54655B2 (sr) 2009-10-27 2021-04-29 Amgen Res Munich Gmbh Dozni režim za primenu cd19xcd3 bispecifičnog antitela
CN103459425B (zh) * 2010-10-27 2015-11-25 安进研发（慕尼黑）股份有限公司 用于治疗dlbcl的组合物
EA026075B1 (ru) * 2010-11-10 2017-02-28 Эмджен Рисерч (Мьюник) Гмбх Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами
KR102345943B1 (ko) * 2011-04-28 2021-12-31 암젠 리서치 (뮌헨) 게엠베하 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
DK3105252T3 (da) * 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
SI3149480T1 (sl) 2014-05-30 2019-05-31 Amgen Research (Munich) Gmbh Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
WO2016109549A1 (en) 2014-12-30 2016-07-07 University Of Utah Research Foundation Hdac1,2 inhibitors and methods of using the same
EP3262217A4 (en) 2015-02-24 2018-07-18 BioAtla LLC Conditionally active biological proteins
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
AU2016263464B2 (en) * 2015-05-20 2021-12-23 Amgen Research (Munich) Gmbh B-cell depletion as a diagnostic marker
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
JP7680358B2 (ja) * 2019-01-30 2025-05-20 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー 癌抗原を標的とするｄｎａコード化二重特異性ｔ細胞エンゲージャーおよび癌治療薬における使用方法
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2021014644A (es) * 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4415829A1 (en) 2021-10-15 2024-08-21 Amgen Research (Munich) GmbH Subcutaneous administration of cd19-binding t cell engaging antibodies
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
US7112324B1 (en) * 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
BG65066B1 (bg) * 1998-04-21 2007-01-31 Micromet Gessellschaft Fur Biomedicinische Forschung Mbh CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ
JP2008501621A (ja) * 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
MXPA06004035A (es) * 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
HRP20150175T1 (en) 2005-12-16 2015-03-27 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101695327B1 (ko) * 2008-11-07 2017-01-11 암젠 리서치 (뮌헨) 게엠베하 급성 림프구성 백혈병의 치료방법
CA2747835A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010083442A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2763633A1 (en) * 2009-05-27 2010-12-02 Gary T. Wang Pyrimidine inhibitors of kinase activity
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
RS54655B2 (sr) * 2009-10-27 2021-04-29 Amgen Res Munich Gmbh Dozni režim za primenu cd19xcd3 bispecifičnog antitela

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456731A (zh) * 2014-02-28 2017-02-22 詹森生物科技公司 用于治疗急性成淋巴细胞性白血病的抗cd38抗体
CN106456731B (zh) * 2014-02-28 2021-02-05 詹森生物科技公司 用于治疗急性成淋巴细胞性白血病的抗cd38抗体
CN107995913A (zh) * 2015-05-18 2018-05-04 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
US11028142B2 (en) 2015-05-18 2021-06-08 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN107995913B (zh) * 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN114634943A (zh) * 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
US11965012B2 (en) 2015-05-18 2024-04-23 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN105154440A (zh) * 2015-08-14 2015-12-16 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
CN105154440B (zh) * 2015-08-14 2016-11-30 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
CN108884166A (zh) * 2016-02-19 2018-11-23 诺瓦斯科普知识产权有限公司 工程改造的细胞和方法
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN111315780A (zh) * 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺

Also Published As

Publication number Publication date
EP2982696A2 (en) 2016-02-10
KR101695327B1 (ko) 2017-01-11
DK2982696T3 (da) 2019-05-27
SMT201500328B (it) 2016-02-25
SI2982696T1 (sl) 2019-06-28
AU2017219083A1 (en) 2017-09-14
RU2011122819A (ru) 2012-12-20
DK2342227T3 (en) 2016-02-15
US20190300609A1 (en) 2019-10-03
US20130323247A1 (en) 2013-12-05
AU2015238784A1 (en) 2015-10-29
JP5955921B2 (ja) 2016-07-20
JP2015057417A (ja) 2015-03-26
AU2018260815B2 (en) 2020-03-05
WO2010052014A1 (en) 2010-05-14
BRPI0921482A2 (pt) 2016-01-12
ES2558434T3 (es) 2016-02-04
HUE028175T2 (en) 2016-12-28
CN107184977A (zh) 2017-09-22
ZA201103255B (en) 2013-12-23
NZ591311A (en) 2012-10-26
EP2982696B1 (en) 2019-03-27
EP2982696A3 (en) 2016-02-17
CY1122366T1 (el) 2021-01-27
EP2342227B1 (en) 2015-10-07
ES2727585T3 (es) 2019-10-17
ME02363B (me) 2016-06-20
HRP20190912T1 (hr) 2019-07-26
CY1117033T1 (el) 2017-04-05
BRPI0921482B1 (pt) 2022-09-20
US20240109964A1 (en) 2024-04-04
AU2009313040A1 (en) 2010-05-14
AU2009313040B2 (en) 2015-07-09
HK1220705A1 (en) 2017-05-12
HRP20151168T1 (hr) 2015-12-04
MX2011002927A (es) 2011-04-11
LT2982696T (lt) 2019-06-10
HK1158668A1 (en) 2012-07-20
RS54456B1 (sr) 2016-06-30
RS58827B1 (sr) 2019-07-31
PT2342227E (pt) 2015-11-13
IL212652A0 (en) 2011-07-31
US11597766B2 (en) 2023-03-07
EP2342227A1 (en) 2011-07-13
AU2018260815A1 (en) 2018-11-22
CA2742249A1 (en) 2010-05-14
CA2742249C (en) 2020-07-21
PT2982696T (pt) 2019-06-04
KR20110091668A (ko) 2011-08-12
JP2012508164A (ja) 2012-04-05
AU2017219083B2 (en) 2018-08-09
SMT201900278T1 (it) 2019-07-11
ME03480B (me) 2020-01-20
PL2982696T3 (pl) 2019-08-30
BRPI0921482A8 (pt) 2017-07-11
PL2342227T3 (pl) 2016-04-29
SI2342227T1 (sl) 2015-12-31
IL212652A (en) 2015-05-31
JP5647132B2 (ja) 2014-12-24
RU2536940C2 (ru) 2014-12-27
HUE043326T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
US20240109964A1 (en) Treatment of acute lymphoblastic leukemia
RU2736802C2 (ru) Новое лечение острого лимфобластного лейкоза у детей
HK1220705B (en) Treatment of acute lymphoblastic leukemia
HK1158668B (en) Treatment of acute lymphoblastic leukemia
HK40022438A (en) Treatment of pediatric acute lymphoblastic leukemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Munich, Germany

Applicant after: AMGEN RESEARCH (MUNICH) GmbH

Address before: Munich, Germany

Applicant before: Matt mikeluo Limited by Share Ltd.

Address after: Munich, Germany

Applicant after: Matt mikeluo Limited by Share Ltd.

Address before: Munich, Germany

Applicant before: Micromet AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: MICROMET AG TO: AMGEN RESEARCH MUNICH GMBH

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111005